Eli Lilly (LLY) expects that its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks said in an interview with Bloomberg TV at the JPMorgan Healthcare Conference in San Francisco. The drugmaker expects data on the pill, called orforglipron, to arrive before the middle of 2025, which could lead to clearance in early 2026, Ricks said. A weight loss pill would offer more convenience to patients and would be easier to manufacture, he added.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
- Verve Therapeutics announces anticipated 2025 milestones
- Potential acquisition of Scorpion positive for Relay, says Barclays
- Lilly in advanced talks to buy cancer biotech Scorpion for up to $2.5B, FT says
- Argus reveals top stock picks for 2025